Last Updated

13 Mar 2019

Artesunate-mefloquine vs Chloroquine in patients with acute uncomplicated P. knowlesi and P. vivax malaria: a randomized open label trial in Sabah, Malaysia (ACT KNOW)

Objectives

The overall goal of this project is to test whether the fixed combination of artesunate-mefloquine is superior to chloroquine in order to define the optimal treatment for both uncomplicated P. knowlesi and P. vivax infection in both adults and children in this region.

Principal Investigator
Rationale and Abstract

Preliminary studies have supported the background efficacy of local standard anti-malarial medications in the treatment of uncomplicated knowlesi malaria, however, this has not been tested systematically and there are no current WHO treatment guidelines for this infection. There are both health cost benefits to a more rapidly acting agent, and due to difficulties with microscopic identification, there may be more effective treatment for all malaria species if an aligned treatment guideline could be supported. In addition, no therapeutic efficacy monitoring of current first-line antimalarials used for the treatment of P. vivax malaria has been conducted in Malaysia.

ClinicalTrials.gov Identifier: NCT01708876

Study Design
Study Type  : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment